ArriVent Biopharma, a company committed to advancing groundbreaking biopharmaceutical products on a global scale, has successfully raised an impressive $615.5 million in funding. The company's mission is to fast-track the development of innovative drug candidates from various sources, including emerging biotech hubs like China. By leveraging its extensive network and engaging in strategic partnerships with other biopharma leaders, ArriVent aims to bring much-needed medicines to patients worldwide, particularly focusing on addressing unmet medical needs in diverse disease areas, with an initial emphasis on oncology. This substantial funding will enable ArriVent to bolster its efforts in revolutionizing the pharmaceutical landscape, making significant strides towards enhancing patient care and outcomes.
ArriVent Biopharma Secures $615.5 Million in Funding to Drive Global Biopharmaceutical Innovation
Recently funded 路 $615.5MBiotechnology Research
Get the full ArriVent Biopharma company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
